Transfusion-associated graft versus host disease epidemiology and demographics

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The incidence in immunocompromised patients receiving blood transfusions is estimated to be 0.1 – 1.0%, mortality around 80 – 90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation, where the engrafted lymphoid cells in the bone marrow are of donor origin; therefore, the immune reaction is not directed against them.

Template:WH Template:WS